Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $34.25.
A number of brokerages recently commented on DNLI. The Goldman Sachs Group upped their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a research note on Monday, May 11th. Robert W. Baird boosted their price target on shares of Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Wall Street Zen upgraded shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright increased their price objective on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th.
Get Our Latest Research Report on Denali Therapeutics
Institutional Investors Weigh In On Denali Therapeutics
Denali Therapeutics Stock Performance
Shares of NASDAQ DNLI opened at $21.04 on Monday. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $19.73 and its two-hundred day moving average price is $19.26. Denali Therapeutics has a 52-week low of $12.58 and a 52-week high of $23.77. The stock has a market capitalization of $3.34 billion, a P/E ratio of -7.31 and a beta of 1.03.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the business earned ($0.78) EPS. As a group, sell-side analysts forecast that Denali Therapeutics will post -2.74 earnings per share for the current year.
Denali Therapeutics Company Profile
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.
Further Reading
- Five stocks we like better than Denali Therapeutics
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
